Print-Friendly PDF Print this page

Kingsley Taft is a senior partner and national co-chair of Goodwin Procter’s Life Sciences Practice. He has over 17 years of experience representing biotechnology, pharmaceutical, medical device and medtech companies in all aspects of their business and legal affairs, including VC financings, strategic alliances, M&A and IPOs. Mr. Taft also serves on the firm's Executive Committee.

Mr. Taft often serves as outside general counsel to life sciences companies, closely advising management and directors as these companies raise capital, in-license and acquire IP and other assets, and then partner their technology, all with a view towards growth and liquidity. In addition, he regularly advises on licenses, JVs, strategic alliances, collaborations and royalty monetizations.

Mr. Taft has been recognized as one of the nation’s leading life sciences attorneys by a variety of publications, including Chambers USA. His legal expertise is complemented by a robust science background, including a Ph.D. in Chemistry from MIT.

Strategic Alliances and M&A

  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, total value in excess of $1 billion
  • F-star Alpha in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
  • Moderna Therapeutics in strategic transactions with Merck, Alexion Pharmaceuticals and AstraZeneca with upfront deal value in excess of $350 million plus downstream payments
  • Teva Pharmaceuticals in its $200 million cash acquisition of Labrys Biologics, total potential purchase price of $825 million
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
  • Royalty Pharma in its $485 million acquisition of royalty rights to ibrutinib from Quest Diagnostics
  • bluebird bio in its global collaboration with Celgene for gene therapies to treat cancer with deal value up to $300 million
  • Avila Therapeutics in its sale to Celgene for up to $925 million, $350 million at closing

Public Offerings

  • aTyr Pharma in its $75 million initial public offering and earlier $76 million Series E financing
  • Blueprint Medicines in its $147 million initial public offering
  • Foundation Medicine in its $106 million initial public offering
  • Fate Therapeutics in its $40 million initial public offering and subsequent $30 million follow-on offering  
  • Omthera Pharmaceuticals in its $64 million initial public offering 

Venture Financings

  • Pronutria Biosciences in its $39 million Series C financing to advance clinical development programs for its amino acid-based products
  • Semma Therapeutics in its $44 million Series A financing and separate collaboration agreement with Novartis to develop stem cell therapies for Type 1 diabetes
  • Moderna Therapeutics in its $450 million and $110 million financings to advance its messenger RNA therapeutics platform
  • Surface Oncology in its $35 million Series A to develop cancer immunotherapies
  • Blueprint Medicines in its $40 million Series A, $25 million Series B, and $50 million Series C financings to advance oncology-focused therapeutics
  • Padlock Therapeutics in its $23 million Series A financing to develop medicines targeting PADs and immune complexes in autoimmune diseases
  • Scholar Rock in its $20 million Series A financing to advance niche modulator therapeutics that target specific growth factors present in fibrosis, musculoskeletal and autoimmune diseases
  • Aerpio Therapeutics in several rounds of venture financing for $60 million to research vascular disease therapies
  • SetPoint Medical in its $27 million Series B financing to commercialize its implantable neuromodulation devices
  • NABsys in several rounds of venture financing for $40 million to advance its genomic analysis technology

Mr. Taft has been recognized by numerous legal guides for his business work and his life sciences industry expertise. He was recently inducted into the LMG Life Sciences Hall of Fame, an honor recognizing only a handful of professionals who have demonstrated outstanding contributions to the life sciences legal space during their careers. He is consistently listed by Chambers USA: America’s Leading Lawyers for Business in Life Sciences: Corporate/Commercial at the national level. Mr. Taft has also been named as a leading business lawyer by U.S. News-Best Lawyers (Biotechnology Law), LMG Life Sciences (Life Sciences Star), The Legal 500 United States (Healthcare: Life Sciences and Venture Capital and Emerging Companies), PLC Cross-border Life Sciences Handbook (Commercial and Partnering), IAM Patent 1000 (Licensing) and The International Who’s Who of Life Sciences Lawyers (Transactional).

Under his leadership, Goodwin Procter’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year three years running (2013-2015), and perennial nationwide recognition by Chambers USA.

Mr. Taft frequently serves as a guest speaker at conferences and industry meetings on strategic and corporate issues affecting life sciences clients. While attending law school, he served as an Editor and then as an Executive Editor of the Harvard Law Review.